To move toward more effective treatments, scientists need to understand the genetic, biological and clinical processes involved in early-onset Alzheimer’s disease (also called younger-onset Alzheimer’s disease). The Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) will explore the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s variant.
Individuals with younger-onset Alzheimer’s disease (including mild cognitive impairment due to Alzheimer’s disease and probable Alzheimer’s disease dementia) and those without Alzheimer’s can potentially participate in LEADS. You may be eligible if:
You are between the ages of 40 and 64.
You are fluent in English.
You are in good general health and have not experienced another neurologic disorder.
You have a family member, friend or caregiver who can provide additional information about your lifestyle.
Ongoing participation is critical to the success of LEADS. Participants with early-onset Alzheimer’s disease will attend three study visits over two years, and participants without Alzheimer’s disease will participate for two visits over one year. Each study visit will be split across multiple days.Activities include:
LEADS is enrolling participants at research sites across the country. If you are ready to take the next step, view the listing of locations to find contact information for the site closest to you. Do you have a question about LEADS? Call us at 877.385.3237 (877.38LEADS). Without clinical trials, there can be no better treatments, no prevention and no cure for Alzheimer's disease. Learn more about the background of the LEADS study at LEADS-study.org.